Clinical Trial Update: An Expanded Access Program to Axitinib is Available for Patients With Advanced Forms of Kidney Cancer (Ductal; Papillary; Chromophobic; Oncocytic) With Mutations in VHL, PBRM1 / BAP1, SETD2, VEGF)

View source ↗

Summary

An expanded access program for Axitinib in advanced renal cell carcinoma (including tumors with VHL, PBRM1/BAP1, SETD2 mutations) is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)

Snippet

Sponsor: Lynkcell Europe | Conditions: Clear Cell Kidney Cancer, Kidney Cancer | Status: NO_LONGER_AVAILABLE